ArticleJournal of pharmacy & bioallied sciences2025
Hepatocellular Carcinoma in South Indian Population: Clinical Profile and AFP Correlation with Radiological Tumor Size.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To study the clinical profile of hepatocellular carcinoma (HCC) in a tertiary care hospital and alpha fetoprotein correlation (AFP) with radiological tumor size. Materials and Methods: A prospective observational study was conducted from February 2023 to August 2024. There were 57 cases of HCC enrolled. Patient details were noted, such as demographics, clinical characteristics, tumor characteristics, disease severity and their treatment. The data was compiled and analyzed. The outcome measures were association of tumor size with AFP levels. Results: Patients had a mean age of 63.1 years and a BMI of 27.02 kg/m². Common risk factors were diabetes mellitus and alcohol in 47.4% and 43.9%, respectively. The common symptoms were abdominal pain (right hypochondrium) in 40 (70.2%) patients, abdominal distension in 36 (63.2%), jaundice in 19 (33.3%), weight loss in 10 (17.5%), fever in 8 (14.0%). Hepatomegaly was present in 29 (50.9%) patients, ascites in 27 (47.4%), splenomegaly in 10 (17.5%), liver bruit and pleural effusion in 6 (10.5%) patients each, and hepatic encephalopathy in 4 (7.0%) patients. Conclusion: HCC patients were primarily older men with diabetes and alcohol being common risk factors. Abdominal pain and distention remain common findings with complications of cirrhosis, esophageal varices, and pleural effusion. AFP levels and imaging modalities were the most important aids for the diagnosis, management and prognosis. Majority of the treatment remains supportive in the form of transarterial chemoembolization (TACE), transarterial radioembolization (TARE), stereotactic body radiation therapy (SBRT) etc. with few cases demanding interventional therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.